Metronidazole Svp Pharma (Metronidazole)

Metronidazole enters anaerobic microorganisms and is reduced to reactive nitro radicals. These radicals damage DNA and inhibit nucleic acid synthesis, disrupting essential metabolic processes and leading to irreversible cell death of the targeted bacteria or protozoa.

The specific dose and infusion rate are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other individual factors. No standardized regimen is provided here.

Metronidazole is classified as pregnancy category unknown in many regions. It should be used only when the potential benefit justifies the potential risk to the fetus. Caution is advised during breastfeeding, and the prescriber should evaluate the risk‑benefit ratio.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and import documentation.

The primary alternative to metronidazole for anaerobic and protozoal infections is tinidazole, which has a longer half‑life and may require less frequent dosing. Clindamycin is another option for anaerobic bacteria but lacks activity against protozoa. Choice depends on pathogen susceptibility, patient tolerance, and clinical context.

Metronidazole Svp Pharma should be stored at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct light, and avoid freezing. Follow standard aseptic techniques when preparing the intravenous infusion.

The product is supplied as an intravenous solution and is administered by slow infusion into a vein, usually diluted in compatible IV fluids. Administration rate and duration are set by the treating physician according to the infection being treated and patient-specific factors.

Serious adverse events include severe allergic reactions such as anaphylaxis, seizures, Stevens‑Johnson syndrome, liver toxicity, peripheral neuropathy, and pancytopenia. Patients should be monitored for any new neurological symptoms, skin reactions, or signs of hepatic dysfunction, and therapy should be stopped immediately if these occur.

Metronidazole should be avoided in individuals with known hypersensitivity to metronidazole or other nitroimidazoles, in patients with severe hepatic impairment, and in those who are in the first trimester of pregnancy unless the benefit outweighs the risk. Caution is also advised for patients with blood dyscrasias or significant renal dysfunction.